Search research articles
Contact Us
Filters
Showing results (131-140 of 139) with videos related to
Page
of 14
Sort By:
You have reached the last page of results.
This site can display upto 139 results.
Cancer Discovery
|
September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Javier Pascual, Joline S J Lim, Iain R Macpherson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Albert Gris-Oliver, Marta Palafox, Laia Monserrat, et al.
Cancer Research
|
February 18, 2026
LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma
Renée L Flaherty, Flavia Hughes, George Sflomos, et al.
Cancer Discovery
|
June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Nature Communications
|
September 7, 2022
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer
Marta Palafox, Laia Monserrat, Meritxell Bellet, et al.
Nature Communications
|
November 14, 2022
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer
Marta Palafox, Laia Monserrat, Meritxell Bellet, et al.
Biorxiv : the Preprint Server for Biology
|
September 10, 2024
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer
Anton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Dejan Juric, Kyung Song, Radia M Johnson, et al.
Nature
|
March 4, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer
Anton Safonov, Minna Lee, David N Brown, et al.
Page
of 14
Search research articles
Search
Showing results (131-140 of 139) with videos related to
Sort By:
Page
of 14
You have reached the last page of results.
This site can display upto 139 results.
Cancer Discovery
|
September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Javier Pascual, Joline S J Lim, Iain R Macpherson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Albert Gris-Oliver, Marta Palafox, Laia Monserrat, et al.
Cancer Research
|
February 18, 2026
LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma
Renée L Flaherty, Flavia Hughes, George Sflomos, et al.
Cancer Discovery
|
June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Nature Communications
|
September 7, 2022
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer
Marta Palafox, Laia Monserrat, Meritxell Bellet, et al.
Nature Communications
|
November 14, 2022
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer
Marta Palafox, Laia Monserrat, Meritxell Bellet, et al.
Biorxiv : the Preprint Server for Biology
|
September 10, 2024
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer
Anton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Dejan Juric, Kyung Song, Radia M Johnson, et al.
Nature
|
March 4, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer
Anton Safonov, Minna Lee, David N Brown, et al.
Page
of 14